Galderma Group AG (FRA:PY30) ROCE % : 6.31% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Galderma Group AG's annualized ROCE % for the quarter that ended in Dec. 2024 was 6.31%.

Galderma Group AG ROCE % Historical Data

The historical data trend for Galderma Group AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG ROCE % Chart

Galderma Group AG Annual Data

Trend

Dec23

Dec24

ROCE %

5.28

6.18

Galderma Group AG Semi-Annual Data
	Jun23	Dec23	Jun24	Dec24
ROCE %	-	5.39	5.88	6.31

Galderma Group AG ROCE % Calculation

Galderma Group AG's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	636.03	/	( ( (11435.907 - 1440.607)	+	(12049.235 - 1459.24) )	/ 2 )
	=	636.03	/	( (9995.3	+	10589.995)	/ 2 )
	=	636.03	/	10292.6475
	=	6.18 %

Galderma Group AG's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	658.95	/	( ( (11685.891 - 1391.642)	+	(12049.235 - 1459.24) )	/ 2 )
	=	658.95	/	( ( 10294.249	+	10589.995 )	/ 2 )
	=	658.95	/	10442.122
	=	6.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Galderma Group AG (FRA:PY30) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Galderma Group AG ROCE % Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GALDY:USA GDERF:USA GALDz:UK GALD:Switzerland

Address

Zahlerweg 10, Zug, CHE, 6300

Website

https://www.galderma.com

Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines